Education
About Us
Working with TipRanks
Follow Us
TransMedics Group Inc (TMDX)
NASDAQ:TMDX
TMDX Stock Chart & Stats
$133.99
-$4.08(-5.19%)
At close: 4:00 PM EST
$133.99
-$4.08(-5.19%)
Day’s Range― - ―
52-Week Range$62.07 - $156.00
Previous CloseN/A
Volume1.17M
Average Volume (3M)654.54K
Market Cap
$4.58B
Enterprise Value$4.69B
Total Cash (Recent Filing)$466.17M
Total Debt (Recent Filing)$519.35M
Price to Earnings (P/E)54.1
Beta1.03
Next Earnings
Mar 04, 2026EPS Estimate
0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.66
Shares Outstanding34,174,324
10 Day Avg. Volume784,155
30 Day Avg. Volume654,540
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)9.06
Price to Sales (P/S)4.69
P/FCF Ratio-25.60
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue8.28
Enterprise Value/Gross Profit13.74
Enterprise Value/Ebitda35.47
Forecast
1Y Price Target
$146.86Price Target Upside9.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Programs And Geographic ExpansionAnalyst indicates that upcoming heart and lung clinical program results and expansion into Europe could increase device adoption by enabling case stacking and demonstrating clinical benefits.
Product DifferentiationAnalyst notes that the Organ Care System is regarded by leading surgeons as the premier warm-perfusion platform, providing a near-term competitive edge over operator-sensitive or not-yet-approved alternatives.
Transplant Volume GrowthAnalyst highlights growth in liver and lung transplant volumes that supports demand for the company's devices and could lift procedure-related sales.
Bears Say
Adoption EconomicsAnalyst cautions that high procedure-related costs and reliance on aviation create complex economics that could force selective hospital use or dependence on payer carve-outs and third-party financing, limiting broader adoption.
New Competitor ApprovalAnalyst warns that FDA clearance of VitaSmart increases competition in the U.S. liver machine perfusion market and may pressure market share and pricing for the company's liver business.
Revenue Dependence On Volumes And LogisticsAnalyst highlights that revenue is increasingly tied to U.S. transplant trends and aviation flight operations, which magnifies exposure to volume swings and logistics disruptions.
TransMedics Group News
TMDX FAQ
What was TransMedics Group Inc’s price range in the past 12 months?
TransMedics Group Inc lowest stock price was $62.07 and its highest was $156.00 in the past 12 months.
What is TransMedics Group Inc’s market cap?
TransMedics Group Inc’s market cap is $4.58B.
When is TransMedics Group Inc’s upcoming earnings report date?
TransMedics Group Inc’s upcoming earnings report date is Mar 04, 2026 which is in 28 days.
How were TransMedics Group Inc’s earnings last quarter?
TransMedics Group Inc released its earnings results on Oct 29, 2025. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.361 by $0.299.
Is TransMedics Group Inc overvalued?
According to Wall Street analysts TransMedics Group Inc’s price is currently Undervalued.
Does TransMedics Group Inc pay dividends?
TransMedics Group Inc does not currently pay dividends.
What is TransMedics Group Inc’s EPS estimate?
TransMedics Group Inc’s EPS estimate is 0.39.
How many shares outstanding does TransMedics Group Inc have?
TransMedics Group Inc has 34,174,324 shares outstanding.
What happened to TransMedics Group Inc’s price movement after its last earnings report?
TransMedics Group Inc reported an EPS of $0.66 in its last earnings report, beating expectations of $0.361. Following the earnings report the stock price went up 1.094%.
Which hedge fund is a major shareholder of TransMedics Group Inc?
Currently, no hedge funds are holding shares in TMDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TransMedics Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$146.86 (9.61% Upside)
$146.86 (9.61% Upside)
Blogger Sentiment
Bullish
TMDX Sentiment 84%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 89.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $257.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 3.9%
Last 30 Days ▲ 3.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
98.35%
12-Months-Change
Fundamentals
Return on Equity
32.48%
Trailing 12-Months
Asset Growth
20.43%
Trailing 12-Months
Company Description
TransMedics Group Inc
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
TMDX Company Deck
TMDX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented strong year-over-year growth and operational achievements, such as significant revenue growth, improved margins, and international expansion plans. However, there were also challenges including a seasonal slowdown and sequential revenue decline. The overall sentiment is balanced with more highlights than lowlights.View all TMDX earnings summariesTMDX Stock 12 Month Forecast
Average Price Target
$146.86
▲(9.61% Upside)
Technical Analysis
Ownership Overview
3.59% Insiders
41.59% Mutual Funds
0.84% Other Institutional Investors
30.32% Public Companies and Individual Investors